Analysts: Cigna’s GLP-1 Program May Help Employers Save Significant Money

May 30
May 30, 2025

The Cigna Group could deliver its employer clients at least 10% in net cost savings on their GLP-1 medication spending thanks to two recent initiatives, according to a May 23 research note from Guggenheim Securities analysts. Meanwhile, Deutsche Bank analysts in a May 23 note wrote that Cigna expects to reduce the net cost of GLP-1 prescriptions by up to 20%. Both Guggenheim and Deutsche Bank analysts met this month with Cigna executives and discussed their approaches to managing GLP-1s and other topics.

Cigna’s Evernorth Health Services subsidiary on May 22 announced that it had struck deals with Eli Lilly and Co. and Novo Nordisk to cap Zepbound (tirzepatide) and Wegovy (semaglutide) copays at $200 per month for plan members, which could save members up to $3,600 per year compared to buying the weight loss medications directly from manufacturers. 
Read more
© 2025 MMIT

Tim Casey

Tim has been a reporter and editor for newspapers, websites and magazines for more than 20 years, including 10 years covering health care business topics. He has a deep knowledge of the managed care industry and pharmacy benefit management. He also has experience covering medical conferences and clinical and legislative health care issues. In 2014, the Society for Advancing Business Editing and Writing selected Tim as one of 15 journalists to participate in a national symposium on the Affordable Care Act. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.